{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:25:57Z","timestamp":1792787157595,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of anti-diabetic agents; however, concerns have been raised about their potential to induce euglycemic ketoacidosis and to increase both glucose production and glucagon secretion. The mechanisms behind these alterations are unknown. Here we show that the SGLT2 inhibitor (SGLT2i) dapagliflozin promotes ketoacidosis in both healthy and type 2 diabetic rats in the setting of insulinopenia through increased plasma catecholamine and corticosterone concentrations secondary to volume depletion. These derangements increase white adipose tissue (WAT) lipolysis and hepatic acetyl-CoA content, rates of hepatic glucose production, and hepatic ketogenesis. Treatment with a loop diuretic, furosemide, under insulinopenic conditions replicates the effect of dapagliflozin and causes ketoacidosis. Furthermore, the effects of SGLT2 inhibition to promote ketoacidosis are independent from hyperglucagonemia. Taken together these data in rats identify the combination of insulinopenia and dehydration as a potential target to prevent euglycemic ketoacidosis\u00a0associated with SGLT2i.<\/jats:p>","DOI":"10.1038\/s41467-019-08466-w","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:06:04Z","timestamp":1549001164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Dehydration and insulinopenia are necessary and sufficient for\u00a0euglycemic ketoacidosis in SGLT2 inhibitor-treated rats"],"prefix":"10.1038","volume":"10","author":[{"given":"Rachel J.","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Rabin-Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joongyu D.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Kibbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-5668","authenticated-orcid":false,"given":"Gerald I.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"8466_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jdiacomp.2016.02.015","volume":"30","author":"NB Jorgensen","year":"2016","unstructured":"Jorgensen, N. B., Pedersen, J. & Vaag, A. A. EMPA-REG: glucose excretion and lipid mobilization-not storage -saves lives. J. Diabetes Complicat. 30, 753 (2016).","journal-title":"J. Diabetes Complicat."},{"key":"8466_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","volume":"19","author":"P Martens","year":"2017","unstructured":"Martens, P., Mathieu, C. & Verbrugge, F. H. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr. Treat. Options Cardiovasc. Med. 19, 23 (2017).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"8466_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia, G. et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 68, 1355\u20131364 (2016).","journal-title":"Hypertension"},{"key":"8466_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber, M. A. et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 4, 211\u2013220 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"8466_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B. & List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853\u2013862 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"8466_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","volume":"39","author":"D Fitchett","year":"2018","unstructured":"Fitchett, D. et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur. Heart J. 39, 363\u2013370 (2018).","journal-title":"Eur. Heart J."},{"key":"8466_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jacc.2017.11.022","volume":"71","author":"D Fitchett","year":"2018","unstructured":"Fitchett, D. et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J. Am. Coll. Cardiol. 71, 364\u2013367 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"8466_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356\u2013363 (2018).","journal-title":"Diabetes Care"},{"key":"8466_CR9","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor, S. I., Blau, J. E. & Rother, K. I. SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849\u20132852 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"8466_CR10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern With SGLT2 inhibitors. Diabetes Care 38, 1638\u20131642 (2015).","journal-title":"Diabetes Care"},{"key":"8466_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jemermed.2016.07.082","volume":"52","author":"TJ Andrews","year":"2017","unstructured":"Andrews, T. J., Cox, R. D., Parker, C. & Kolb, J. Euglycemic diabetic ketoacidosis with elevated acetone in a patient taking a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor. J. Emerg. Med. 52, 223\u2013226 (2017).","journal-title":"J. Emerg. Med."},{"key":"8466_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2169\/internalmedicine.56.7501","volume":"56","author":"J Adachi","year":"2017","unstructured":"Adachi, J., Inaba, Y. & Maki, C. Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin. Intern. Med. 56, 187\u2013190 (2017).","journal-title":"Intern. Med."},{"key":"8466_CR13","doi-asserted-by":"crossref","first-page":"232470961771004","DOI":"10.1177\/2324709617710040","volume":"5","author":"S Pujara","year":"2017","unstructured":"Pujara, S. & Ioachimescu, A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J. Investig. Med. High. Impact Case Rep. 5, 2324709617710040 (2017).","journal-title":"J. Investig. Med. High. Impact Case Rep."},{"key":"8466_CR14","doi-asserted-by":"crossref","first-page":"232470961771273","DOI":"10.1177\/2324709617712736","volume":"5","author":"DA Kelmenson","year":"2017","unstructured":"Kelmenson, D. A. et al. Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin. J. Investig. Med. High. Impact Case Rep. 5, 2324709617712736 (2017).","journal-title":"J. Investig. Med. High. Impact Case Rep."},{"key":"8466_CR15","doi-asserted-by":"crossref","unstructured":"Blau J. E., Tella S. H., Taylor S. I., Rother K. I. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab. Res. Rev. 33, e2924 (2017).","DOI":"10.1002\/dmrr.2924"},{"key":"8466_CR16","doi-asserted-by":"crossref","first-page":"232470961772535","DOI":"10.1177\/2324709617725351","volume":"5","author":"C Bowman","year":"2017","unstructured":"Bowman, C., Abramson, V. & Wellons, M. Ketoacidosis with canagliflozin prescribed for phosphoinositide 3-kinase inhibitor-induced hyperglycemia: a case report. J. Investig. Med. High. Impact Case Rep. 5, 2324709617725351 (2017).","journal-title":"J. Investig. Med. High. Impact Case Rep."},{"key":"8466_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jemermed.2017.10.001","volume":"54","author":"F Brown","year":"2018","unstructured":"Brown, F. & McColl, T. Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report. J. Emerg. Med. 54, 109\u2013111 (2018).","journal-title":"J. Emerg. Med."},{"key":"8466_CR18","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"EJ Meyer","year":"2018","unstructured":"Meyer, E. J., Gabb, G. & Jesudason, D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications. Diabetes Care 41, e47\u2013e49 (2018).","journal-title":"Diabetes Care"},{"key":"8466_CR19","doi-asserted-by":"publisher","first-page":"e11056","DOI":"10.1097\/MD.0000000000011056","volume":"97","author":"YM Chou","year":"2018","unstructured":"Chou, Y. M. et al. Euglycemic diabetic ketoacidosis caused by dapagliflozin: a case report. Medicine 97, e11056 (2018).","journal-title":"Medicine"},{"key":"8466_CR20","doi-asserted-by":"crossref","unstructured":"Karakaya Z., Topal F. E., Topal F., Payza U., Akyol P. Y. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin. Am. J. Emerg. Med. 36, 2136-e1 (2018).","DOI":"10.1016\/j.ajem.2018.08.054"},{"key":"8466_CR21","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick, M., Schneeweiss, S. & Patorno, E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N. Engl. J. Med. 376, 2300\u20132302 (2017).","journal-title":"N. Engl. J. Med."},{"key":"8466_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini, E. et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40, 771\u2013776 (2017).","journal-title":"Diabetes Care"},{"key":"8466_CR23","doi-asserted-by":"crossref","unstructured":"Garg S. K., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. New Eng. J. Med. 377, 2337\u20132348 (2017).","DOI":"10.1056\/NEJMoa1708337"},{"key":"8466_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2337\/dc15-1995","volume":"39","author":"AL Peters","year":"2016","unstructured":"Peters, A. L., Henry, R. R., Thakkar, P., Tong, C. & Alba, M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 39, 532\u2013538 (2016).","journal-title":"Diabetes Care"},{"key":"8466_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jphs.2016.06.004","volume":"131","author":"A Tahara","year":"2016","unstructured":"Tahara, A., Takasu, T., Yokono, M., Imamura, M. & Kurosaki, E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice. J. Pharmacol. Sci. 131, 198\u2013208 (2016).","journal-title":"J. Pharmacol. Sci."},{"key":"8466_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11\u201326 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"8466_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499\u2013508 (2014).","journal-title":"J. Clin. Invest."},{"key":"8466_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509\u2013514 (2014).","journal-title":"J. Clin. Invest."},{"key":"8466_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner, C. et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21, 512\u2013517 (2015).","journal-title":"Nat. Med."},{"key":"8466_CR30","doi-asserted-by":"crossref","unstructured":"Solini, A., et al. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 43, 512\u2013520 (2017).","DOI":"10.1016\/j.diabet.2017.04.002"},{"key":"8466_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep31214","volume":"6","author":"MG Pedersen","year":"2016","unstructured":"Pedersen, M. G., Ahlstedt, I., El Hachmane, M. F. & Gopel, S. O. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci. Rep. 6, 31214 (2016).","journal-title":"Sci. Rep."},{"key":"8466_CR32","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele, G. et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39, 2036\u20132041 (2016).","journal-title":"Diabetes Care"},{"key":"8466_CR33","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190\u20131195 (2016).","journal-title":"Diabetes"},{"key":"8466_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono, M. et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol. 727, 66\u201374 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"8466_CR35","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/nutd.2014.20","volume":"4","author":"M Suzuki","year":"2014","unstructured":"Suzuki, M. et al. Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr. Diabetes 4, e125 (2014).","journal-title":"Nutr. Diabetes"},{"key":"8466_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.tem.2015.05.011","volume":"26","author":"RG Kibbey","year":"2015","unstructured":"Kibbey, R. G. SGLT-2 inhibition and glucagon: Cause for alarm? Trends Endocrinol. Metab. 26, 337\u2013338 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"8466_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.4158\/EP14489.OR","volume":"20","author":"L Hansen","year":"2014","unstructured":"Hansen, L., Iqbal, N., Ekholm, E., Cook, W. & Hirshberg, B. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr. Pract. 20, 1187\u20131197 (2014).","journal-title":"Endocr. Pract."},{"key":"8466_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","volume":"184","author":"JJ Cohen","year":"1956","unstructured":"Cohen, J. J., Berglund, F. & Lotspeich, W. D. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am. J. Physiol. 184, 91\u201396 (1956).","journal-title":"Am. J. Physiol."},{"key":"8466_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1172\/JCI108764","volume":"60","author":"JD McGarry","year":"1977","unstructured":"McGarry, J. D., Mannaerts, G. P. & Foster, D. W. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J. Clin. Invest. 60, 265\u2013270 (1977).","journal-title":"J. Clin. Invest."},{"key":"8466_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0005-2760(78)90150-9","volume":"530","author":"JD McGarry","year":"1978","unstructured":"McGarry, J. D., Mannaerts, G. P. & Foster, D. W. Characteristics of fatty acid oxidation in rat liver homogenates and the inhibitory effect of malonyl-CoA. Biochim. Biophys. Acta 530, 305\u2013313 (1978).","journal-title":"Biochim. Biophys. Acta"},{"key":"8466_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cell.2017.12.001","volume":"172","author":"RJ Perry","year":"2018","unstructured":"Perry, R. J. et al. Leptin mediates a glucose-fatty acid cycle to maintain glucose homeostasis in starvation. Cell 172, 234\u2013248 (2018).","journal-title":"Cell"},{"key":"8466_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1172\/JCI88477","volume":"127","author":"RJ Perry","year":"2017","unstructured":"Perry, R. J. et al. Mechanism for leptin\u2019s acute insulin-independent effect to reverse diabetic ketoacidosis. J. Clin. Invest. 127, 657\u2013669 (2017).","journal-title":"J. Clin. Invest."},{"key":"8466_CR43","doi-asserted-by":"crossref","unstructured":"Perry, R. J. et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Med. 20, 759 (2014).","DOI":"10.1038\/nm.3579"},{"key":"8466_CR44","doi-asserted-by":"crossref","unstructured":"Perry, R. J. et al. Leptin mediates a glucose-fatty acid cycle to maintain glucose homeostasis in starvation. Cell 172, 234\u2013248 (2018).","DOI":"10.1016\/j.cell.2017.12.001"},{"key":"8466_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1053\/meta.2000.17721","volume":"49","author":"MJ Reed","year":"2000","unstructured":"Reed, M. J. et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390\u20131394 (2000).","journal-title":"Metabolism"},{"key":"8466_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","volume":"160","author":"RJ Perry","year":"2015","unstructured":"Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745\u2013758 (2015).","journal-title":"Cell"},{"key":"8466_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1126\/science.1439783","volume":"258","author":"JD McGarry","year":"1992","unstructured":"McGarry, J. D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258, 766\u2013770 (1992).","journal-title":"Science"},{"key":"8466_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1172\/JCI118846","volume":"98","author":"K Rebrin","year":"1996","unstructured":"Rebrin, K., Steil, G. M., Mittelman, S. D. & Bergman, R. N. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J. Clin. Invest. 98, 741\u2013749 (1996).","journal-title":"J. Clin. Invest."},{"key":"8466_CR49","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1172\/JCI119867","volume":"100","author":"SD Mittelman","year":"1997","unstructured":"Mittelman, S. D., Fu, Y. Y., Rebrin, K., Steil, G. & Bergman, R. N. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. J. Clin. Invest. 100, 3121\u20133130 (1997).","journal-title":"J. Clin. Invest."},{"key":"8466_CR50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12881","volume":"19","author":"H Al Jobori","year":"2017","unstructured":"Al Jobori, H. et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes. Metab. 19, 809\u2013813 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"8466_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40268-016-0137-9","volume":"16","author":"A Okamoto","year":"2016","unstructured":"Okamoto, A., Yokokawa, H., Sanada, H. & Naito, T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R. D. 16, 255\u2013261 (2016).","journal-title":"Drugs R. D."},{"key":"8466_CR52","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00125-015-3845-8","volume":"59","author":"E Muscelli","year":"2016","unstructured":"Muscelli, E. et al. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. Diabetologia 59, 700\u2013708 (2016).","journal-title":"Diabetologia"},{"key":"8466_CR53","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak, M. J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60, 890\u2013898 (2011).","journal-title":"Diabetes"},{"key":"8466_CR54","doi-asserted-by":"publisher","first-page":"C1277","DOI":"10.1152\/ajpcell.00296.2010","volume":"299","author":"AS Yu","year":"2010","unstructured":"Yu, A. S. et al. Functional expression of SGLTs in rat brain. Am. J. Physiol. Cell. Physiol. 299, C1277\u2013C1284 (2010).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"8466_CR55","doi-asserted-by":"crossref","unstructured":"Vieira E., Liu Y. J., Gylfe E. Involvement of alpha1 and beta-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse alpha-cell. Naunyn Schmiedebergs Arch. Pharmacol. 369, 179\u2013183 (2004).","DOI":"10.1007\/s00210-003-0858-5"},{"key":"8466_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1172\/JCI109294","volume":"63","author":"E Samols","year":"1979","unstructured":"Samols, E. & Weir, G. C. Adrenergic modulation of pancreatic A, B, and D cells alpha-Adrenergic suppression and beta-adrenergic stimulation of somatostatin secretion, alpha-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J. Clin. Invest. 63, 230\u2013238 (1979).","journal-title":"J. Clin. Invest."},{"key":"8466_CR57","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1172\/JCI107395","volume":"52","author":"J Iversen","year":"1973","unstructured":"Iversen, J. Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J. Clin. Invest. 52, 2102\u20132116 (1973).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08466-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T14:57:50Z","timestamp":1671202670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08466-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8466"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-08466-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.I.S. is on the Scientific Advisory Boards for Merck, NovoNordisk, AstraZeneca, Aegerion, iMBP, Jansen Research and Development and receives investigator-initiated support from Gilead Sciences, Merck and AstraZeneca. This study was funded by an investigator-initiated award to R.J.P. and G.I.S. from Astra Zeneca. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"548"}}